Global Leader and Pioneer in RNAi Technology and Oligonucleotide Drug Development
We are one of the earliest pioneers in oligonucleotide drugs, committed to advancing RNA interference (RNAi) technology and the industrialization of oligonucleotide drugs. We have established an oligonucleotide therapeutic platform that vertically integrates the complete set of technologies to support the full lifecycle from early R&D to commercialization. We have built a globally integrated drug development capability and a rich siRNA pipeline, covering cardiovascular, metabolic, renal, liver, and other diseases, especially chronic disease treatment.
With a globally proprietary innovation R&D platform, we encompass the full lifecycle technology of oligonucleotide drugs from early research to commercialization, including drug delivery, chemical modification, multi-target drug development, model-informed drug development, pharmacology research and manufacturing. Among them, our proprietary liver-targeted delivery platform RiboGalSTARTM, has advanced several products into the clinical phase II stage, with excellent clinical validation of effectiveness and safety. Our partnership with one of the globally recognized pharmaceutical companies stands out as the sole platform-level collaboration between a China-based biotech company and a global MNC in the RNAi space, reflecting the high degree of recognition by multinational pharmaceutical companies of our R&D platform and scientific research strength.
With a forward-looking global strategy, we have established R&D centers in Beijing and Suzhou, China, as well as in Europe.
International R&D Center
Our international R&D center, Ribocure Pharmaceuticals AB, was established in February 2022 in Gothenburg, Sweden. Serving as our global hub for clinical and business development, Ribocure is staffed by a highly skilled team with international expertise and a strong track record in global clinical development. The center is equipped with advanced biology laboratories and a clinical Phase II trial facility, playing a leading role in driving clinical research and commercial advancement worldwide.


Management Team
-
Dr. Zicai Liang
Founding Chairman, CEO
-
Dr. Liming Gan
Co-CEO, President of Global Product R&D
-
Dr. Hongyan Zhang
Founding President
-
Mr. Su Zhang
Chief Financial Officer, Secretary of the Board, Company Secretary
-
Dr. Cheng (Charles) Tong
Executive Vice President
-
Dr. Shan Gao
Senior Vice President, Chief Scientific Officer
-
Dr. Anders Gabrielsen
Vice President, Global Head of Clinical Development
-
Dr. John Taylor
Vice President, Global Head of Business Development

History
-
2025
-
2024
-
2023
-
2022
-
2021
-
2020
-
2019
-
2017
-
2016
-
2015
-
2010
-
2008
-
2007
Our Values
We are guided by scientific rigor and uphold core values of pioneering innovation, efficiency, collaboration, integrity, and responsibility.
With commitment to patient-centric R&D, we drive transformative progress in global health through oligonucleotide therapeutics.

